APO Research
Talk to an analyst

APO RESEARCH · REPORT

Kidney Fibrosis Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Kidney Fibrosis Drugs Industry Growth and Trends Forecast to 2032

22 December 202599 pages

Choose your research edition.

Industry ResearchKidney Fibrosis Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Kidney Fibrosis Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Kidney Fibrosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Kidney Fibrosis Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Kidney Fibrosis Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Kidney Fibrosis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Kidney Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Kidney Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Kidney Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Kidney Fibrosis Drugs include Merck and Co, F. Hoffman-La Roche, Pfizer Inc, ProMetic Life-Sciences Inc, La Jolla Pharmaceutical Company, InterMune Inc, Genzyme Corporation, Galectin Therapeutics and BioLine Rx, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Kidney Fibrosis Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Kidney Fibrosis Drugs market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Kidney Fibrosis Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Kidney Fibrosis Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Kidney Fibrosis Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Kidney Fibrosis Drugs Market by Company

Merck and Co

F. Hoffman-La Roche

Pfizer Inc

ProMetic Life-Sciences Inc

La Jolla Pharmaceutical Company

InterMune Inc

Genzyme Corporation

Galectin Therapeutics

BioLine Rx

Kidney Fibrosis Drugs Segment by Type

Angiotensin Converting Enzyme (ACE) Inhibitors

Angiotensin II Receptor Blockers (ARBs)

Renin Inhibitors

Vasopeptidase Inhibitors

Pirfenidone

Kidney Fibrosis Drugs Segment by Application

Chronic Kidney Diseases

Kidney Cancer Treatment

Others

Kidney Fibrosis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Fibrosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Kidney Fibrosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Fibrosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Kidney Fibrosis Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Kidney Fibrosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Angiotensin Converting Enzyme (ACE) Inhibitors Table 2. Major Company of Angiotensin II Receptor Blockers (ARBs) Table 3. Major Company of Renin Inhibitors Table 4. Major Company of Vasopeptidase Inhibitors Table 5. Major Company of Pirfenidone Table 6. Global Kidney Fibrosis Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Kidney Fibrosis Drugs Sales by Type (2021-2026) & (k units) Table 8. Global Kidney Fibrosis Drugs Sales Market Share in Volume by Type (2021-2026) Table 9. Global Kidney Fibrosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 10. Global Kidney Fibrosis Drugs Sales Market Share in Value by Type (2021-2026) Table 11. Global Kidney Fibrosis Drugs Price by Type (2021-2026) & (US$/unit) Table 12. Global Kidney Fibrosis Drugs Sales by Type (2027-2032) & (k units) Table 13. Global Kidney Fibrosis Drugs Sales Market Share in Volume by Type (2027-2032) Table 14. Global Kidney Fibrosis Drugs Sales by Type (2027-2032) & (US$ Million) Table 15. Global Kidney Fibrosis Drugs Sales Market Share in Value by Type (2027-2032) Table 16. Global Kidney Fibrosis Drugs Price by Type (2027-2032) & (US$/unit) Table 17. North America Kidney Fibrosis Drugs Sales by Type (2021-2026) & (k units) Table 18. North America Kidney Fibrosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Kidney Fibrosis Drugs Sales by Type (2021-2026) & (k units) Table 20. Europe Kidney Fibrosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Kidney Fibrosis Drugs Sales by Type (2021-2026) & (k units) Table 22. Asia-Pacific Kidney Fibrosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Kidney Fibrosis Drugs Sales by Type (2021-2026) & (k units) Table 24. Latin America Kidney Fibrosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Kidney Fibrosis Drugs Sales by Type (2021-2026) & (k units) Table 26. Middle East and Africa Kidney Fibrosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 27. Kidney Fibrosis Drugs Industry Trends Table 28. Kidney Fibrosis Drugs Industry Drivers Table 29. Kidney Fibrosis Drugs Industry Opportunities and Challenges Table 30. Kidney Fibrosis Drugs Industry Restraints Table 31. Global Kidney Fibrosis Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Kidney Fibrosis Drugs Revenue Market Share by Company (2021-2026) Table 33. Global Kidney Fibrosis Drugs Sales by Company (2021-2026) & (k units) Table 34. Global Kidney Fibrosis Drugs Sales Share by Company (2021-2026) Table 35. Global Kidney Fibrosis Drugs Market Price by Company (2021-2026) & (US$/unit) Table 36. Global Kidney Fibrosis Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Kidney Fibrosis Drugs Major Company Production Sites and Headquarters Table 38. Global Kidney Fibrosis Drugs Company, Product Type & Application Table 39. Global Kidney Fibrosis Drugs Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Kidney Fibrosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Kidney Fibrosis Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Kidney Fibrosis Drugs Sales by Region (2021-2026) & (k units) Table 44. Global Kidney Fibrosis Drugs Sales Market Share in Volume by Region (2021-2026) Table 45. Global Kidney Fibrosis Drugs Sales by Region (2021-2026) & (US$ Million) Table 46. Global Kidney Fibrosis Drugs Sales Market Share in Value by Region (2021-2026) Table 47. Global Kidney Fibrosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 48. Global Kidney Fibrosis Drugs Sales by Region (2027-2032) & (k units) Table 49. Global Kidney Fibrosis Drugs Sales Market Share in Volume by Region (2027-2032) Table 50. Global Kidney Fibrosis Drugs Sales by Region (2027-2032) & (US$ Million) Table 51. Global Kidney Fibrosis Drugs Sales Market Share in Value by Region (2027-2032) Table 52. Global Kidney Fibrosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 53. Global Kidney Fibrosis Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Kidney Fibrosis Drugs Sales by Application (2021-2026) & (k units) Table 55. Global Kidney Fibrosis Drugs Sales Market Share in Volume by Application (2021-2026) Table 56. Global Kidney Fibrosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 57. Global Kidney Fibrosis Drugs Sales Market Share in Value by Application (2021-2026) Table 58. Global Kidney Fibrosis Drugs Price by Application (2021-2026) & (US$/unit) Table 59. Global Kidney Fibrosis Drugs Sales by Application (2027-2032) & (k units) Table 60. Global Kidney Fibrosis Drugs Sales Market Share in Volume by Application (2027-2032) Table 61. Global Kidney Fibrosis Drugs Sales by Application (2027-2032) & (US$ Million) Table 62. Global Kidney Fibrosis Drugs Sales Market Share in Value by Application (2027-2032) Table 63. Global Kidney Fibrosis Drugs Price by Application (2027-2032) & (US$/unit) Table 64. North America Kidney Fibrosis Drugs Sales by Application (2021-2026) & (k units) Table 65. North America Kidney Fibrosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Kidney Fibrosis Drugs Sales by Application (2021-2026) & (k units) Table 67. Europe Kidney Fibrosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Kidney Fibrosis Drugs Sales by Application (2021-2026) & (k units) Table 69. Asia-Pacific Kidney Fibrosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Kidney Fibrosis Drugs Sales by Application (2021-2026) & (k units) Table 71. Latin America Kidney Fibrosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Kidney Fibrosis Drugs Sales by Application (2021-2026) & (k units) Table 73. Middle East and Africa Kidney Fibrosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 74. Merck and Co Company Information Table 75. Merck and Co Business Overview Table 76. Merck and Co Kidney Fibrosis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Merck and Co Kidney Fibrosis Drugs Product Portfolio Table 78. Merck and Co Recent Development Table 79. F. Hoffman-La Roche Company Information Table 80. F. Hoffman-La Roche Business Overview Table 81. F. Hoffman-La Roche Kidney Fibrosis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. F. Hoffman-La Roche Kidney Fibrosis Drugs Product Portfolio Table 83. F. Hoffman-La Roche Recent Development Table 84. Pfizer Inc Company Information Table 85. Pfizer Inc Business Overview Table 86. Pfizer Inc Kidney Fibrosis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Pfizer Inc Kidney Fibrosis Drugs Product Portfolio Table 88. Pfizer Inc Recent Development Table 89. ProMetic Life-Sciences Inc Company Information Table 90. ProMetic Life-Sciences Inc Business Overview Table 91. ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Product Portfolio Table 93. ProMetic Life-Sciences Inc Recent Development Table 94. La Jolla Pharmaceutical Company Company Information Table 95. La Jolla Pharmaceutical Company Business Overview Table 96. La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Product Portfolio Table 98. La Jolla Pharmaceutical Company Recent Development Table 99. InterMune Inc Company Information Table 100. InterMune Inc Business Overview Table 101. InterMune Inc Kidney Fibrosis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. InterMune Inc Kidney Fibrosis Drugs Product Portfolio Table 103. InterMune Inc Recent Development Table 104. Genzyme Corporation Company Information Table 105. Genzyme Corporation Business Overview Table 106. Genzyme Corporation Kidney Fibrosis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Genzyme Corporation Kidney Fibrosis Drugs Product Portfolio Table 108. Genzyme Corporation Recent Development Table 109. Galectin Therapeutics Company Information Table 110. Galectin Therapeutics Business Overview Table 111. Galectin Therapeutics Kidney Fibrosis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Galectin Therapeutics Kidney Fibrosis Drugs Product Portfolio Table 113. Galectin Therapeutics Recent Development Table 114. BioLine Rx Company Information Table 115. BioLine Rx Business Overview Table 116. BioLine Rx Kidney Fibrosis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. BioLine Rx Kidney Fibrosis Drugs Product Portfolio Table 118. BioLine Rx Recent Development Table 119. North America Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 120. North America Kidney Fibrosis Drugs Sales by Country (2021-2026) & (k units) Table 121. North America Kidney Fibrosis Drugs Sales Market Share by Country (2021-2026) Table 122. North America Kidney Fibrosis Drugs Sales Forecast by Country (2027-2032) & (k units) Table 123. North America Kidney Fibrosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 124. North America Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 125. North America Kidney Fibrosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 126. North America Kidney Fibrosis Drugs Market Share by Country (2021-2026) Table 127. North America Kidney Fibrosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 128. North America Kidney Fibrosis Drugs Market Share Forecast by Country (2027-2032) Table 129. Europe Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 130. Europe Kidney Fibrosis Drugs Sales by Country (2021-2026) & (k units) Table 131. Europe Kidney Fibrosis Drugs Sales Market Share by Country (2021-2026) Table 132. Europe Kidney Fibrosis Drugs Sales Forecast by Country (2027-2032) & (k units) Table 133. Europe Kidney Fibrosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 134. Europe Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. Europe Kidney Fibrosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 136. Europe Kidney Fibrosis Drugs Market Share by Country (2021-2026) Table 137. Europe Kidney Fibrosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. Europe Kidney Fibrosis Drugs Market Share Forecast by Country (2027-2032) Table 139. Asia-Pacific Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 140. Asia-Pacific Kidney Fibrosis Drugs Sales by Country (2021-2026) & (k units) Table 141. Asia-Pacific Kidney Fibrosis Drugs Sales Market Share by Country (2021-2026) Table 142. Asia-Pacific Kidney Fibrosis Drugs Sales Forecast by Country (2027-2032) & (k units) Table 143. Asia-Pacific Kidney Fibrosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 144. Asia-Pacific Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Asia-Pacific Kidney Fibrosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 146. Asia-Pacific Kidney Fibrosis Drugs Market Share by Country (2021-2026) Table 147. Asia-Pacific Kidney Fibrosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Asia-Pacific Kidney Fibrosis Drugs Market Share Forecast by Country (2027-2032) Table 149. Latin America Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 150. Latin America Kidney Fibrosis Drugs Sales by Country (2021-2026) & (k units) Table 151. Latin America Kidney Fibrosis Drugs Sales Market Share by Country (2021-2026) Table 152. Latin America Kidney Fibrosis Drugs Sales Forecast by Country (2027-2032) & (k units) Table 153. Latin America Kidney Fibrosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 154. Latin America Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 155. Latin America Kidney Fibrosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 156. Latin America Kidney Fibrosis Drugs Market Share by Country (2021-2026) Table 157. Latin America Kidney Fibrosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 158. Latin America Kidney Fibrosis Drugs Market Share Forecast by Country (2027-2032) Table 159. Middle East and Africa Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 160. Middle East and Africa Kidney Fibrosis Drugs Sales by Country (2021-2026) & (k units) Table 161. Middle East and Africa Kidney Fibrosis Drugs Sales Market Share by Country (2021-2026) Table 162. Middle East and Africa Kidney Fibrosis Drugs Sales Forecast by Country (2027-2032) & (k units) Table 163. Middle East and Africa Kidney Fibrosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 164. Middle East and Africa Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 165. Middle East and Africa Kidney Fibrosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 166. Middle East and Africa Kidney Fibrosis Drugs Market Share by Country (2021-2026) Table 167. Middle East and Africa Kidney Fibrosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 168. Middle East and Africa Kidney Fibrosis Drugs Market Share Forecast by Country (2027-2032) Table 169. Key Raw Materials Table 170. Raw Materials Key Suppliers Table 171. Kidney Fibrosis Drugs Distributors List Table 172. Kidney Fibrosis Drugs Customers List Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. Kidney Fibrosis Drugs Image Figure 2. Global Kidney Fibrosis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Kidney Fibrosis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Kidney Fibrosis Drugs Sales (2021-2032) & (k units) Figure 5. Angiotensin Converting Enzyme (ACE) Inhibitors Image Figure 6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales YoY Growth (2021-2032) & (k units) Figure 7. Angiotensin II Receptor Blockers (ARBs) Image Figure 8. Global Angiotensin II Receptor Blockers (ARBs) Sales YoY Growth (2021-2032) & (k units) Figure 9. Renin Inhibitors Image Figure 10. Global Renin Inhibitors Sales YoY Growth (2021-2032) & (k units) Figure 11. Vasopeptidase Inhibitors Image Figure 12. Global Vasopeptidase Inhibitors Sales YoY Growth (2021-2032) & (k units) Figure 13. Pirfenidone Image Figure 14. Global Pirfenidone Sales YoY Growth (2021-2032) & (k units) Figure 15. Global Kidney Fibrosis Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Kidney Fibrosis Drugs Market Share by Type 2025 VS 2032 Figure 17. North America Kidney Fibrosis Drugs Sales Market Share in Volume by Type in 2025 Figure 18. North America Kidney Fibrosis Drugs Sales Market Share in Value by Type in 2025 Figure 19. Europe Kidney Fibrosis Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Europe Kidney Fibrosis Drugs Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Kidney Fibrosis Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Kidney Fibrosis Drugs Sales Market Share in Value by Type in 2025 Figure 23. Latin America Kidney Fibrosis Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Kidney Fibrosis Drugs Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Kidney Fibrosis Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Kidney Fibrosis Drugs Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Kidney Fibrosis Drugs Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Chronic Kidney Diseases Image Figure 30. Global Chronic Kidney Diseases Sales YoY Growth (2021-2032) & (k units) Figure 31. Kidney Cancer Treatment Image Figure 32. Global Kidney Cancer Treatment Sales YoY Growth (2021-2032) & (k units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 35. Global Kidney Fibrosis Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Kidney Fibrosis Drugs Market Share by Application 2025 VS 2032 Figure 37. North America Kidney Fibrosis Drugs Sales Market Share in Volume by Application in 2025 Figure 38. North America Kidney Fibrosis Drugs Sales Market Share in Value by Application in 2025 Figure 39. Europe Kidney Fibrosis Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Europe Kidney Fibrosis Drugs Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Kidney Fibrosis Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Kidney Fibrosis Drugs Sales Market Share in Value by Application in 2025 Figure 43. Latin America Kidney Fibrosis Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Kidney Fibrosis Drugs Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Kidney Fibrosis Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Kidney Fibrosis Drugs Sales Market Share in Value by Application in 2025 Figure 47. North America Kidney Fibrosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. North America Kidney Fibrosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Kidney Fibrosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Kidney Fibrosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Kidney Fibrosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Europe Kidney Fibrosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Kidney Fibrosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Kidney Fibrosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Kidney Fibrosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Asia-Pacific Kidney Fibrosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Kidney Fibrosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Kidney Fibrosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Kidney Fibrosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Latin America Kidney Fibrosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Kidney Fibrosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Kidney Fibrosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Kidney Fibrosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 64. Middle East and Africa Kidney Fibrosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Kidney Fibrosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Kidney Fibrosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Kidney Fibrosis Drugs Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Kidney Fibrosis Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Angiotensin II Receptor Blockers (ARBs)
  • Renin Inhibitors
  • Vasopeptidase Inhibitors
  • Pirfenidone
Applications
  • Chronic Kidney Diseases
  • Kidney Cancer Treatment
  • Others
Companies covered
  • Merck and Co
  • F. Hoffman-La Roche
  • Pfizer Inc
  • ProMetic Life-Sciences Inc
  • La Jolla Pharmaceutical Company
  • InterMune Inc
  • Genzyme Corporation
  • Galectin Therapeutics
  • BioLine Rx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Kidney Fibrosis Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Kidney Fibrosis Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Kidney Fibrosis Drugs Market by Type
  6. 1.3.1 Angiotensin Converting Enzyme (ACE) Inhibitors
  7. 1.3.2 Angiotensin II Receptor Blockers (ARBs)
  8. 1.3.3 Renin Inhibitors
  9. 1.3.4 Vasopeptidase Inhibitors
  10. 1.3.5 Pirfenidone
  11. 1.4 Global Kidney Fibrosis Drugs Market Size by Type
  12. 1.4.1 Global Kidney Fibrosis Drugs Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Kidney Fibrosis Drugs Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Kidney Fibrosis Drugs Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Kidney Fibrosis Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Kidney Fibrosis Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Kidney Fibrosis Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Kidney Fibrosis Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Kidney Fibrosis Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Kidney Fibrosis Drugs Industry Trends
  2. 2.2 Kidney Fibrosis Drugs Industry Drivers
  3. 2.3 Kidney Fibrosis Drugs Industry Opportunities and Challenges
  4. 2.4 Kidney Fibrosis Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Kidney Fibrosis Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Kidney Fibrosis Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Kidney Fibrosis Drugs Price (2021-2026)
  4. 3.4 Global Kidney Fibrosis Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Kidney Fibrosis Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Kidney Fibrosis Drugs Company, Product Type & Application
  7. 3.7 Global Kidney Fibrosis Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Kidney Fibrosis Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Kidney Fibrosis Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Kidney Fibrosis Drugs Tier 1, Tier 2, and Tier 3
4 Kidney Fibrosis Drugs Regional Status and Outlook
  1. 4.1 Global Kidney Fibrosis Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Kidney Fibrosis Drugs Historic Market Size by Region
  3. 4.2.1 Global Kidney Fibrosis Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Kidney Fibrosis Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Kidney Fibrosis Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Kidney Fibrosis Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Kidney Fibrosis Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Kidney Fibrosis Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Kidney Fibrosis Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Kidney Fibrosis Drugs by Application
  1. 5.1 Kidney Fibrosis Drugs Market by Application
  2. 5.1.1 Chronic Kidney Diseases
  3. 5.1.2 Kidney Cancer Treatment
  4. 5.1.3 Others
  5. 5.2 Global Kidney Fibrosis Drugs Market Size by Application
  6. 5.2.1 Global Kidney Fibrosis Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Kidney Fibrosis Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Kidney Fibrosis Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Kidney Fibrosis Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Kidney Fibrosis Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Kidney Fibrosis Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Kidney Fibrosis Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Kidney Fibrosis Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Merck and Co
  2. 6.1.1 Merck and Co Company Information
  3. 6.1.2 Merck and Co Business Overview
  4. 6.1.3 Merck and Co Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Merck and Co Kidney Fibrosis Drugs Product Portfolio
  6. 6.1.5 Merck and Co Recent Developments
  7. 6.2 F. Hoffman-La Roche
  8. 6.2.1 F. Hoffman-La Roche Company Information
  9. 6.2.2 F. Hoffman-La Roche Business Overview
  10. 6.2.3 F. Hoffman-La Roche Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 F. Hoffman-La Roche Kidney Fibrosis Drugs Product Portfolio
  12. 6.2.5 F. Hoffman-La Roche Recent Developments
  13. 6.3 Pfizer Inc
  14. 6.3.1 Pfizer Inc Company Information
  15. 6.3.2 Pfizer Inc Business Overview
  16. 6.3.3 Pfizer Inc Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Inc Kidney Fibrosis Drugs Product Portfolio
  18. 6.3.5 Pfizer Inc Recent Developments
  19. 6.4 ProMetic Life-Sciences Inc
  20. 6.4.1 ProMetic Life-Sciences Inc Company Information
  21. 6.4.2 ProMetic Life-Sciences Inc Business Overview
  22. 6.4.3 ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Product Portfolio
  24. 6.4.5 ProMetic Life-Sciences Inc Recent Developments
  25. 6.5 La Jolla Pharmaceutical Company
  26. 6.5.1 La Jolla Pharmaceutical Company Company Information
  27. 6.5.2 La Jolla Pharmaceutical Company Business Overview
  28. 6.5.3 La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Product Portfolio
  30. 6.5.5 La Jolla Pharmaceutical Company Recent Developments
  31. 6.6 InterMune Inc
  32. 6.6.1 InterMune Inc Company Information
  33. 6.6.2 InterMune Inc Business Overview
  34. 6.6.3 InterMune Inc Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 InterMune Inc Kidney Fibrosis Drugs Product Portfolio
  36. 6.6.5 InterMune Inc Recent Developments
  37. 6.7 Genzyme Corporation
  38. 6.7.1 Genzyme Corporation Company Information
  39. 6.7.2 Genzyme Corporation Business Overview
  40. 6.7.3 Genzyme Corporation Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Genzyme Corporation Kidney Fibrosis Drugs Product Portfolio
  42. 6.7.5 Genzyme Corporation Recent Developments
  43. 6.8 Galectin Therapeutics
  44. 6.8.1 Galectin Therapeutics Company Information
  45. 6.8.2 Galectin Therapeutics Business Overview
  46. 6.8.3 Galectin Therapeutics Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Galectin Therapeutics Kidney Fibrosis Drugs Product Portfolio
  48. 6.8.5 Galectin Therapeutics Recent Developments
  49. 6.9 BioLine Rx
  50. 6.9.1 BioLine Rx Company Information
  51. 6.9.2 BioLine Rx Business Overview
  52. 6.9.3 BioLine Rx Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 BioLine Rx Kidney Fibrosis Drugs Product Portfolio
  54. 6.9.5 BioLine Rx Recent Developments
7 North America by Country
  1. 7.1 North America Kidney Fibrosis Drugs Sales by Country
  2. 7.1.1 North America Kidney Fibrosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Kidney Fibrosis Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Kidney Fibrosis Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Kidney Fibrosis Drugs Market Size by Country
  6. 7.2.1 North America Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Kidney Fibrosis Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Kidney Fibrosis Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Kidney Fibrosis Drugs Sales by Country
  2. 8.1.1 Europe Kidney Fibrosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Kidney Fibrosis Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Kidney Fibrosis Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Kidney Fibrosis Drugs Market Size by Country
  6. 8.2.1 Europe Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Kidney Fibrosis Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Kidney Fibrosis Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Kidney Fibrosis Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Kidney Fibrosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Kidney Fibrosis Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Kidney Fibrosis Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Kidney Fibrosis Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Kidney Fibrosis Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Kidney Fibrosis Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Kidney Fibrosis Drugs Sales by Country
  2. 10.1.1 South America Kidney Fibrosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Kidney Fibrosis Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Kidney Fibrosis Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Kidney Fibrosis Drugs Market Size by Country
  6. 10.2.1 South America Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Kidney Fibrosis Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Kidney Fibrosis Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Kidney Fibrosis Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Kidney Fibrosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Kidney Fibrosis Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Kidney Fibrosis Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Kidney Fibrosis Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Kidney Fibrosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Kidney Fibrosis Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Kidney Fibrosis Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Kidney Fibrosis Drugs Value Chain Analysis
  2. 12.1.1 Kidney Fibrosis Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Kidney Fibrosis Drugs Production Mode & Process
  7. 12.2 Kidney Fibrosis Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Kidney Fibrosis Drugs Distributors
  10. 12.2.3 Kidney Fibrosis Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst